<DOC>
	<DOCNO>NCT01130701</DOCNO>
	<brief_summary>In study , new chemotherapeutic agent , panitumumab , test combination another chemotherapeutic drug , capecitabine , along external radiotherapy , find whether combination effective safe use surgery .</brief_summary>
	<brief_title>A Pilot Study Evaluate Efficacy Safety Neoadjuvant Chemoradiotherapy With Capecitabine , . . .</brief_title>
	<detailed_description>Surgical resection remain standard procedure patient localize resectable pancreatic cancer . Neoadjuvant preoperative therapy chemotherapy radiation therapy propose alternative approach patient localize pancreatic adenocarcinoma . Advantages : 1 ) early start systemic therapy target micrometastatic disease ; 2 ) increase compliance chemoradiotherapy ; 3 ) increase primary tumor complete resection rate ; 4 ) avoidance surgery patient rapidly develop metastatic disease ; 5 ) importantly , provide important resource research term tissue acquisition therapy . Finally , opportunity test safety efficacy novel combination weekly panitumumab , oral capecitabine radiation pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Cytological histological confirmation pancreatic adenocarcinoma require . 2 . Only patient localize apparently resectable , nonmetastatic tumor eligible . All patient must stag chest Xray chest CT abdominal pelvic CT scan MRI . One follow radiological criterion must meet recorded chart dedicate surgeon prior enrollment . A ) Localized , potentially resectable : 1 ) evidence tumor extension celiac axis , hepatic artery superior mesenteric artery ; 2 ) evidence tumor encasement occlusion superior mesenteric vein ( SMV ) SMV/portal vein ( PV ) confluence ; 3 ) evidence visceral peritoneal metastasis B ) Borderline resectable : 1 ) extra pancreatic disease , ( 2 ) follow possible tumorvessel relationship : SMVPV confluence reconstruct even short segment venous occlusion present ; tumor abutment SMA ≤180° ; short segment encasement hepatic artery amenable resection reconstruction . Patients follow radiological criterion NOT eligible : A ) Locally advanced disease : ( 1 ) extra pancreatic disease , ( 2 ) tumor encasement SMA celiac axis define tumor involvement &gt; 180° arterial circumference . B ) Radiographic evidence distant organ peritoneal metastasis . 3 . Age &gt; 18 year . 4 . ECOG performance status 0 1 . 5 . Patient must adequate hematological , renal hepatic function define : WBC &gt; 2,000 cells/mm3 ANC &gt; 1500 cells/mm3 Hemoglobin &gt; 9.0 g/dL Platelets &gt; 100,000 cells/mm3 Serum creatinine &lt; 1.5 x upper limit normal ( UNL ) calculate creatinine clearance &gt; 50 mL/min calculate CockcroftGault method Total bilirubin &lt; 2.5 mg/dl AST &lt; 3x upper limit normal ALT &lt; 3x upper limit normal 6 . Serum calcium magnesium level within limit normal 7 . Patients may prior therapy carcinoma pancreas , prior abdominal radiation therapy . 1 . Patients malignancy within 5 year study entry , except curatively treat basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix . 2 . Psychiatric illness would prevent patient give informed consent . 3 . Serious medical illness would limit anticipated survival &lt; 12 week . 4 . Protocol treatment would pose significant risk unborn child . Pregnant woman enrol , woman childbearing age strongly encourage practice effective birth control six month trial . Nonpregnant nonbreastfeeding . Female participant childbearing potential must negative urine serum pregnancy test prior registration . Perimenopausal participant must amenorrheic &gt; 12 month consider childbearing potential . All patient ( men woman ) reproductive potential must agree use effective method birthcontrol receive study therapy six month completion therapy . 5 . Inability swallow medication . Patients adequate , unassisted oral intake . 6 . Inability hold still cooperate radiotherapy . 7 . Prior history interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Capecitabine</keyword>
</DOC>